Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance On-Demand Webinar Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…Danielle Pillsbury2025年5月23日
CERTAINTY 2025: The power of Model-Informed Drug Development Blog CERTAINTY 2025: The power of Model-Informed Drug Development We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…Certara2025年5月16日
Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk Webinar Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk Jul 24, 2025 - 11am ETDanielle Pillsbury2025年5月5日
Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies Fact Sheet Non-Animal Navigator™: 動物実験の削減、改善、代替を実現する戦略とAIを活用したシミュレーション サターラのNon-Animal Navigator™ソリューションは、企業が最適なNAM戦略を選択し最適化できるよう支援します。Danielle Pillsbury2025年4月30日
Certara Announces Second Annual Certainty U.S. Event Announcement サターラ、第 2 回「Certainty U.S.」イベントの開催を発表 Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…Certara2025年4月22日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions Webinar Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions 2025年6月17日 - 11:00 東部標準時間(ET)Danielle Pillsbury2025年4月21日
In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD) Blog In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD) 2025年4月18日 What’s next for drug development? Recapping our MIDD in the age of…Certara2025年4月18日
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing Press Release Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…Simona Colucci2025年4月14日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication HIV感染でウイルス学的に抑制されている思春期患者における、長時間作用型注射剤カボテグラビルと長時間作用型注射剤リルピビリンの併用療法の安全性(IMPAACT 2017/MOCHA):第1/2相、多施設共同、オープンラベル、非比較、用量設定試験 The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025年3月20日
MIDD in Japan – Implementations, challenges and opportunities Publication MIDD in Japan – Implementations, challenges and opportunities In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…Danielle Pillsbury2025年3月12日